Full Text View
Tabular View
No Study Results Posted
Related Studies
GnRH Agonist and Antagonists in an Oocyte Donation Program
This study has been completed.
First Received: July 23, 2007   Last Updated: January 9, 2009   History of Changes
Sponsored by: Instituto Valenciano de Infertilidad, Spain
Information provided by: Instituto Valenciano de Infertilidad, Spain
ClinicalTrials.gov Identifier: NCT00505817
  Purpose

The primary purpose of this study is to evaluate the effect of the two different protocols (long protocol vs antagonist protocol) on oocyte / embryo quality.


Condition Intervention Phase
Effect of Two Protocols of Ovarian Stimulation on Oocyte Quality
Drug: Cetrorelix and Leuprolide
Phase IV

Drug Information available for: Leuprolide Leuprolide acetate Cetrorelix Cetrorelix acetate
U.S. FDA Resources
Study Type: Interventional
Study Design: Non-Randomized, Open Label, Crossover Assignment

Further study details as provided by Instituto Valenciano de Infertilidad, Spain:

Detailed Description:

The cycles with antagonists of the GnRHa present a series of advantages with respect the GnRHa in an oocyte donation program: treatment cycles are simpler and shorter, a lower amount of dose of gonadotrophins is needed for stimulation, and most important, a decreased rate of ovarian hyperstimulation syndrome is observed. Nevertheless, several clinical trials relate their use to a greater rate of abortion and worse oocyte/ embryo quality. In order to discriminate the endometrial factor from the quality of oocyte cohort, the best strategy is the oocyte donation model. In the present study, for the first time, the effect of different protocols (long versus antagonist protocol) will be studied in the same donor, acting as its own control, undergoing COH. We will compare the COH´s parameters and IVF outcome obtained in the same donor submitted to, firstly, GnRH antagonist protocol (Cetrorelix- n= 45) versus another consecutive cycle with long protocol (Ac. Leuprolide- n= 45).

  Eligibility

Ages Eligible for Study:   18 Years to 34 Years
Genders Eligible for Study:   Female
Criteria

Inclusion Criteria:

  • oocyte donors with age range: 18 - 34; BMI: 18 - 29 kg/m2;

Exclusion Criteria:

  • PCO
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00505817

Locations
Spain
Instituto Valenciano de Infertilidad Spain
Valencia, Spain, 46015
Sponsors and Collaborators
Instituto Valenciano de Infertilidad, Spain
Investigators
Principal Investigator: Marco Melo, MDPhD Instituto Valenciano de Infertilidad
  More Information

No publications provided

Study ID Numbers: VLC-MM-0706-307-19
Study First Received: July 23, 2007
Last Updated: January 9, 2009
ClinicalTrials.gov Identifier: NCT00505817     History of Changes
Health Authority: Spain: Ministry of Health

Study placed in the following topic categories:
Deslorelin
Antineoplastic Agents, Hormonal
Leuprolide
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Cetrorelix
Hormones

Additional relevant MeSH terms:
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Leuprolide
Fertility Agents, Female
Therapeutic Uses
Hormone Antagonists
Fertility Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Cetrorelix
Reproductive Control Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 06, 2009